Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.4% – Should You Buy?

Eli Lilly and Company (NYSE:LLY) traded up 1.4% on Wednesday . The stock traded as high as $922.15 and last traded at $915.7140. 2,155,156 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 3,195,379 shares. The stock had previously closed at $903.02.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Morgan Stanley reiterated an Overweight rating and a $1,313 price target, citing the growth potential of Lilly’s new employer access platform for obesity therapies — a strong sell‑side endorsement that supports upside expectations. Read More.
• Positive Sentiment: Lilly completed a pediatric pharmacokinetics study for a next‑generation diabetes drug (Phase 1 update), de‑risking a program that could expand the diabetes franchise if later‑stage results succeed. Read More.
• Positive Sentiment: Investor letters and coverage note that Lilly’s GLP‑1/obesity drugs remain the core growth driver; RiverPark and other commentators highlight continued revenue momentum that underpins earnings upside. Read More.
• Positive Sentiment: Retail/pharmacy expansion: Kroger pharmacies have begun offering Lilly’s Zepbound KwikPen with support/savings programs, widening patient access and potentially boosting volumes. Read More.
• Positive Sentiment: High‑profile endorsements: Jim Cramer continues to list Lilly among his top healthcare picks, which can attract retail inflows and reinforce positive sentiment. Read More.
• Positive Sentiment: Leadership and pipeline focus: Reporting on an external executive’s role in driving Lilly’s oncology pipeline (Loxo assets) suggests management is prioritizing high‑value R&D initiatives. Read More.
• Neutral Sentiment: Relative valuation and peer comparisons (Novo Nordisk, AbbVie) produce mixed views — analysts debate whether Lilly’s multiple already prices in GLP‑1 growth, leaving valuation as a watchpoint. Read More.
• Neutral Sentiment: Analyst comparisons (LLY vs ABBV) and ETF commentary suggest different playbooks for investors (direct exposure vs diversified healthcare), useful for portfolio positioning but not an immediate catalyst. Read More.
• Negative Sentiment: Lilly plans to phase out select insulin products across Europe by 2027, a move that could modestly disrupt revenue in that region and requires monitoring for transitional volumes/pricing impact. Read More.
• Negative Sentiment: Local scrutiny of a large Lilly development project (LVPC review) raises near‑term execution/permits risk for that specific buildout; operational risk is localized but worth watching. Read More.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Bank of America dropped their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research report on Thursday, February 5th. Barclays began coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective on the stock. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, CICC Research boosted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,221.44.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a 50-day moving average price of $1,016.28 and a 200-day moving average price of $961.72. The company has a market capitalization of $865.18 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 1.06 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the firm earned $5.32 EPS. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of LLY. Brighton Jones LLC lifted its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Schnieders Capital Management LLC. increased its position in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares during the period. Proactive Wealth Strategies LLC lifted its holdings in shares of Eli Lilly and Company by 5.6% during the second quarter. Proactive Wealth Strategies LLC now owns 1,398 shares of the company’s stock worth $1,090,000 after buying an additional 74 shares in the last quarter. Finally, Jefferies Financial Group Inc. boosted its position in shares of Eli Lilly and Company by 35.9% in the second quarter. Jefferies Financial Group Inc. now owns 8,128 shares of the company’s stock valued at $6,336,000 after acquiring an additional 2,146 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.